The manufacturing hold at Emergent's Baltimore Bayview plant could be coming to an end — report
Maryland’s Emergent BioSolutions has been forced to sit on its own hands for more than a month after shutting down production at a Baltimore plant blasted for screwing up millions of doses of two Covid-19 vaccines. Now, with a laundry list of quality issues apparently solved, Emergent is reportedly days away from getting its lines rolling once again.
J&J is expected to announce that contamination problems at Emergent’s Baltimore Bayview plant have been resolved and production is set to resume, The Wall Street Journal reported Friday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.